Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients

Journal of Psychiatry and Neuroscience

Volumn 33, Issue 2, 2008, Pages 123-130

  Lotrich, Francis E ^a   Pollock, Bruce G ^a,c   Kirshner, Margaret ^a   Ferrell, Robert F ^b   Reynolds III, Charles F ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aged; Depression; Paroxetine; Serotonin

Indexed keywords

PAROXETINE; SEROTONIN TRANSPORTER;

AGED; ALLELE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; FEMALE; GENOTYPE; GERIATRIC CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 41149146056     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Driscoll HC, Basinski J, Mulsant BH, et al. Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry 2005;20:661-7.
2. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005;45:1106-22.
3. Whyte EM, Dew MA, Gildengers AG, et al. Time course of response to antidepressants in late-life major depression: therapeutic implications. 2004;21:531-554. Drugs Aging 2004;21:531-54.
4. Bies RR, Feng Y, Lotrich FE, et al. Utility of sparse concentration samploing for citalopram in elderly cinical trial subjects. J Clin Pharmacol 2004;44:1352-9.
5. Serretti A, Artioli P, Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 2005;15:61-7.
6. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006;38:82-94.
7. Preskorn SH. Recent dose-effect studies regarding antidepressants. In: Balant LP, editor. Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs conference held in Badajoz, Spain, October 23-25, 1997. Luxembourg: European Commission, Directorate-General Science, Research and Development; 1998. p. 43-62.
8. Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999;174:297-303.
9. Lotrich FE, Bies R, Muldoon M, et al. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology (Berl) 2005;178:268-75.
10. Papakostas GI, Petersen T, Iosifescu DV, et al. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol 2005;8:59-63.
11. Rausch JL, Johnson ME, Fei Y-J, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002;51:723-32.
12. Sindrup SH, Grodum E, Gram LF, et al. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. Ther Drug Monit 1991;13:408-14.
13. Henry ME, Moore CM, Kaufman MJ, et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 2000;157:1506-8.
14. Hirano K, Kimura R, Sugimoto Y, et al. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 2005;144:695-702.
15. Baker CB, Tweedie R, Duval S, et al. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 2003;17:1-9.
16. Tasker TC, Kaye CM, Zussman BD, et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989; 350:152-5.
17. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154:963-9.
18. Normann C, Horn M, Hummel B, et al. Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry 2004;37:123-6.
19. Reis M, Aberg-Wistedt A, Agren H, et al. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 2004;19:283-91.
20. Lotrich FE, Pollock BG, Ferrell RE. Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics 2001;1:153-64.
21. Kraft JB, Peters EJ, Slager SL, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007;61:734-42.
22. Murphy GMJ, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-9.
23. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-90.
24. Durham LK, Webb SM, Milos PM, et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004;174:525-9.
25. Smith GS, Lotrich FE, Malhotra AK, et al. The effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology 2004;29:2226-31.
26. Heils A, Mossner R, Lesch KP. The human serotonin transporter gene polymorphism - basic research and clinical implication. J Neural Transm Gen Sect 1997;104:1005-14.
27. Rausch JL. Initial conditions of psychotropic drug response: Studies of serotonin transporter long promoter region (5-HTTLPR), serotonin transporter efficiency, cytokine and kinase gene expression relevant to depression and antidepressant outcome. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1046-61.
28. Lotrich FE, Bies RB, Smith GS, et al. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol 2006;20:33-40.
29. Reynolds CF, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006;354:1130-8.
30. Mulsant BH, Pollock BG, Nebes R, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed in patients and outpatients. Am J Geriatr Psychiatry 2001;9:406-14.
31. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
32. Foglia JP, Sorisio DA, Kirshner M, et al. Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997;693:147-51.
33. Kenward M. A method for comparing profiles of repeated measurements. Appl Stat 1987;36:296-308.
34. Oquendo MA, Baca-Garcia E, Kartachov A. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry 2003;64:825-33.
35. Gelernter J, Cubells JF, Kidd JR, et al. Population studies of polymorphisms of the serotonin transporter protein gene. Am J Med Genet 1999;88:61-6.
36. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003;64:413-20.
37. Solai LKK, Pollock BG, Mulsant BH, et al. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 2002;22:481-6.
38. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35.
39. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 2001;62:16-23.
40. Serretti A, Zanardi R, Rossini D, et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001;6:586-92.
41. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-11.
42. Arias B, Catalan R, Gasto C, et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003;23:563-7.
43. Arias B, Gasto C, Catalan R, et al. Variation in the serotonin transporter gene and clinical response to citalopram in major depression. Am J Med Genet 2000;96:536.
44. Parsey RV, Hasting RS, Oquendo MA, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 2006;163:48-51.
45. Simon GE, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408.
46. Devlin B, Roeder K, Wasserman L. Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 2001;60:156-66.
47. Kato M, Ikenaga Y, Wakeno M, et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005;20:151-6.
48. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 2004;60:553-7.
49. Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003;25:738-42.
50. Lotrich FE, Pollock BG. Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatr Dis Treat 2005;1:17-35.
51. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004;60:329-36.
52. Hartter S, Wetzel H, Hammes E, et al. Serum concentrations of fluvoxamine and clinical effects. Pharmacopsychiatry 1998;31:199-200.
53. Hu X, Rush AJ, Charney D, et al. A functional serotonin transporter promoter polymorphism with reduced side effects but not symptomatic outcome with citalopram in adult outpatients with major depression. In press 2007.
54. Gilles M, Deuschle M, Kellner S, et al. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 2005;38:118-21.
55. Mauri MC, Laini V, Bitetto A, et al. Long-term efficacy of paroxetine in major depression: a study with plasma levels, Int J Psychiatry Clin Tract 1999;3:115-9.